Cobas e601

Up to March 2008 LH, FSH, estradiol and TSH levels were measured by chemilu-minescence immunoassay (Siemens Bayer Advia Centaur CP Immunoassay). Since March 2008 LH, FSH, estradiol and TSH were measured by electrochemiluminescence immunoassay (Roche Cobas E 601, module immunology analyzer). SHBG levels were measured by chemiluminescence immunoassay (Siemens Bayer Advia Centaur CP Immunoassay) up to November 2010 and since then by electrochemiluminescence immunoassay (Roche Cobas E 601, module immunology analyzer). Serum levels of Inhibin B were measured by the Beckman Coulter GenII assay.

To assess the anti-biotin interference ability in the sandwich method, we used high-value mixed sera, and for the competitive method, we used low-value mixed sera. These mixed sera, together with 10% biotin solution at concentrations of 0 to 200,000 ng/mL, were labeled from H0 to H17 for the sandwich method and L0 to L17 for the competitive method and were used as the samples in our experiment. The previously prepared M reagents (labeled from M1 to M6) were used as reagents and used for tests with the Cobas e 601 (Roche Diagnostics). The level of and change in optical signal were observed, and a change in the amplitude of the optical signal of ±10% was considered to indicate an improved ability to resist biotin interference.
To assess the impact of the concentration of M on the optical signal level, R1 and R2 reagents were replaced with Roche’s special diluent, a luminescent substance was used as a sample, and M1–M6 were used as M reagents. The Cobas e 601 (Roche Diagnostics) was used to observe the change in light signal.
We also assessed the light transmittance of M1–M6 at a 620-nm wavelength using a 721G spectrophotometer (Shanghai YITIAN Precision Instrument Co. Ltd., Shanghai, China) and adjusted the light transmittance to 100% with the Roche diluent.

Fasting blood samples were also collected for HbA1c, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and free fatty acid (FFA) measurements. Plasma glucose amounts were assessed by the hexokinase method on TBA-200FR (Tokyo, Japan). Insulin concentration was evaluated by a chemiluminescence immunoassay (Cobas e601, Roche). HbA1c was quantitated by high-performance liquid chromatography (Bio-Rad D-10). Triglyceride, total cholesterol, HDL-C, and LDL-C concentrations were assessed by specific immunoassays (Cobas e601, Roche). Serum FFAs were detected via an enzymatic method (DiaSys Diagnostic Systems, Co., Ltd). HOMA-IR was derived as follows: [fasting serum insulin (mU/l) × fasting glucose (mmol/l)]/22.5^{31 (link)}. The Adipo-IR was defined as fasting insulin concentration (mIU/ml) × fasting FFA (mmol/l)^{32 (link),33 (link)}.
Mouse serum was analyzed for FFA using a standard enzymatic assay following the manufacturer’s protocols (ColorfulGene biological technology Co., Ltd, Wuhan, China).

The FNA wash-out specimens were stored at −20 °C and transferred to the clinical laboratory within 1 month for the analysis of Tg. Serum Tg was only measured in patients on the advice of their physicians. The Tg concentrations in both the serum and FNA wash-out were measured with an automated electrochemiluminescence immunoassay (Cobas e 601, Roche Diagnostics, Mannheim, Germany). The minimum detectable Tg concentration was 0.04 ng/mL. The maximum Tg concentration detectable in our laboratory was 500 ng/mL. If the Tg level of the sample was above the maximum value (500 ng/mL), the sample was diluted and examined again. According to previous reports, the cutoff value was far lower than the maximum value [5 (link)–14 (link)]. Therefore, we decided to perform no further examination of the samples with maximum values, and recorded these values as 500+ ng/mL. Serum TgAb was also measured with an automated electrochemiluminescence immunoassay (Cobas e 601, Roche Diagnostics, Mannheim, Germany) with a functional sensitivity of 10 IU/mL.